Vaxart

Vaxart, Inc. operates as a clinical-stage biotechnology company, which engages in the development of oral recombinant vaccines based on its Vector-Adjuvant-Antigen Standardized Technology (VAAST) oral vaccine platform. Its investigational vaccines are administered using a room temperature-stable tablet, rather than by injection. It is developing prophylactic vaccine candidates that target a range of infectious diseases, including SARS-CoV-2, norovirus, seasonal influenza and respiratory syncytial virus (RSV). The company was founded in 2004 and is headquartered in South San Francisco, CA.

Earnings data Q4 2023

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Vaxart, Inc. operates as a clinical-stage biotechnology company, which engages in the development of oral recombinant vaccines based on its Vector-Adjuvant-Antigen Standardized Technology oral vaccine platform. Its investigational vaccines are administered using a room temperature-stable tablet, rather than by injection. It is developing prophylactic vaccine candidates that target a range of infectious diseases, including SARS-CoV-2, norovirus, seasonal influenza and respiratory syncytial virus (RSV). The company was founded in 2004 and is headquartered in South San Francisco, CA.

The coronavirus vaccine maker will participate in a government-funded study.

Why Vaxart Stock Skyrocketed Today

Shares of oral vaccine maker Vaxart Inc (NASDAQ: VXRT) are on a strong two-day run after two announcements tied to coronavirus vaccine development.

Vaxart Rallies On Double Dose Of Positive Coronavirus Vaccine Developments

Vaxart Inc. VXRT, +96.23% said Friday its oral COVID-19 vaccine has been selected to take part in a non-human primate challenge study funded by the U.S.

Vaxart shares skyrocket on news its COVID-19 vaccine candidate to be part of 'Operation Warp Speed'

OWS to Test First Oral COVID-19 Vaccine in Non-Human Primates OWS to Test First Oral COVID-19 Vaccine in Non-Human Primates

Vaxart’s COVID-19 Vaccine Selected for the U.S. Government’s Operation Warp Speed

Inovio Pharmaceuticals

Sorrento Therapeutics

Investors are piling into coronavirus stocks as COVID-19 cases surge.

Why Vaxart, Inovio, and Sorrento Therapeutics Stocks Soared Today

Enabling Production of A Billion or More COVID-19 Vaccine Doses Per Year

Vaxart, Inc. Signs Memorandum of Understanding with Attwill Medical Solutions Sterilflow, LP

SOUTH SAN FRANCISCO, Calif., June  24, 2020  (GLOBE NEWSWIRE) -- Vaxart, Inc. (“Vaxart” or the “Company”), a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, announced today that it has joined the broad-market Russell 3000Ò Index at the conclusion of the 2020 Russell indexes annual reconstitution, effective Monday, June 29th 2020 after the U.S. market opening.

Vaxart, Inc. Set to Join Russell 3000® Index

Vaxart (VXRT) management names Andrei Floroiu as its next chief executive officer with immediate effect. Stock appreciates on this news.

Vaxart Gets New CEO, Focuses on Coronavirus Vaccine Program

Andrei Floroiu Appointed Chief Executive Officer  Wouter Latour, MD, to Continue as  Chairman of the Board

Vaxart, Inc. Appoints New CEO to Accelerate Advancement of COVID-19 and Other Programs

SOUTH SAN FRANCISCO, Calif., June  03, 2020  (GLOBE NEWSWIRE) -- Vaxart, Inc. (“Vaxart” or the “Company”) (NASDAQ: VXRT), a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced today announced that Wouter Latour, MD, chief executive officer of Vaxart is scheduled to present at the Jefferies Virtual Healthcare Conference on Thursday, June 4, 2020 at 2:00 p.m. Eastern Time.

Vaxart to Present at the  Jefferies Virtual Healthcare Conference

KindredBio Selected as Second Contract Manufacturing Organization

Vaxart Announces Selection of its Oral COVID-19 Vaccine Lead Candidate

Lead Vaccine Candidates for COVID-19 are Highly Immunogenic in Preclinical Testing

Vaxart Announces First Quarter 2020 Financial Results and Provides Corporate Update

During Vaxart's (VXRT) upcoming Q1 earnings call, investor focus will be on the company's progress with its oral vaccine candidates against SARS CoV-2.

Vaxart (VXRT) to Report Q1 Earnings: What's in the Cards?

The company released preliminary first-quarter results.

Why Vaxart Stock Slumped Today

The biotech company is benefiting from an overall rise in the stock market.

Why Vaxart Is Soaring Today

Vaxart's (VXRT) several COVID-19 vaccine candidates generate immune responses in pre-clinical studies. Stock rises.

Vaxart Up on Pre-Clinical Data on Coronavirus Vaccine Candidates

Lead Vaccine Candidates Generate Anti-SARS CoV-2 Antibodies in All Tested Animals after First Dose Lead Vaccine Candidates Generate Anti-SARS CoV-2 Antibodies in All Tested Animals after First Dose

Vaxart Announces Positive Pre-Clinical Data for its Oral COVID-19 Vaccine Program

Eli Lilly

Moderna

Regeneron Pharmaceuticals

Sanofi

The whole world has pinned hopes on pharmaceutical and biotech companies to create drugs and vaccine to help combat COVID-19.

Buy 5 Top Medical Stocks on Coronavirus  Drug Trial Results

GlaxoSmithKline

Johnson & Johnson

Just like the flu vaccine, pharmacists should be empowered to administer the COVID-19 vaccine to patients in every state.

Expand Pharmacists’ Authority To Promote COVID-19 Vaccine Access

ProShares Long Online/Short Stores ETF

Co-Diagnostics

CrowdStrike

Domino's Pizza

Emergent BioSolutions

JD.com

Zoom Video

Inside the top-performing sectors of Q1 and their winning stocks.

Top Sectors of Q1 & Their Winning Stocks

Novavax

Roku

Unlike the broader market, these stocks to buy have managed to hold up strong amid the ongoing public health crisis.

5 Stocks to Buy That Are Holding Strong While Everything Else Crumbles

AbbVie

Fast-track approval for coronavirus drug trials is encouraging drug developers. Here are four stocks that can make the most of this phase.

Coronavirus Drug Development Race to Boost These 4 Stocks

Amazon

Clorox

Costco

Even though several companies have suffered badly from the COVID-19 outbreak, here're five that stand to benefit from the pandemic.

Here're the 5 Big Winners from the Coronavirus Pandemic

Emergent BioSolutions (EBS) teams up with Vaxart to support development of the latter's oral vaccine candidate for treating coronavirus disease.

Emergent (EBS) to Help Vaxart Develop Coronavirus Vaccine

Vaxart Inc (NASDAQ: VXRT) shares were advancing Wednesday following an update from the company on its COVID-19 vaccine program.

News for Vaxart Stock (VXRT)